Clinical Evaluation of Maintenance BCG Immunotherapy in Superficial Bladder Tumors
Clinical Evaluation of Maintenance BCG Immunotherapy in Superficial Bladder Tumors
Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.
BCG maintenance immunotherapy 1/3 dose : 27 mg two randomized arms : 3 or 6 months for 36 months clinical side effects according to OMS score efficacy regarding recurrence : cytology and cystoscopy PSA, leucocyturia and N-ramp gene evaluation
Inclusion Criteria:
Exclusion Criteria: